Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (3y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 33.51% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -51.98% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 21.19% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -43.40% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -77.58% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -39.19% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -177.73% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 27.70% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 83.15% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -69.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.92% |
| Mar 31, 2026 | 14.56% |
| Dec 31, 2025 | -47.39% |
| Sep 30, 2025 | 6.48% |
| Jun 30, 2025 | -17.85% |
| Mar 31, 2025 | -93.57% |
| Dec 31, 2024 | -35.52% |
| Sep 30, 2024 | 39.23% |
| Jun 30, 2024 | -110.50% |
| Mar 31, 2024 | -415.75% |
| Dec 31, 2023 | 51.52% |
| Sep 30, 2023 | -24.39% |
| Jun 30, 2023 | -37.36% |
| Mar 31, 2023 | -32.84% |
| Dec 31, 2022 | 28.05% |
| Sep 30, 2022 | -84.09% |
| Jun 30, 2022 | -33.96% |
| Mar 31, 2022 | -55.25% |
| Dec 31, 2021 | 31.51% |
| Sep 30, 2021 | -87.95% |